Pharmaceutical Executive-10-01-2020

When the people are the sole assets.

A recent roundtable moderated by Rob Jekielek of The Harris Poll gathered five biopharma CEOs to discuss the industry’s shifting reputational landscape in the public eye.

How ramped-up support and educational services have helped bridge the chasms and ease fears along the patient care continuum.

Amid attention on coronavirus, efforts to address the burden of non-communicable diseases are at a critical juncture.

Missteps threaten agency’s independence as vaccines seek finish line.

A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.

Tips for rounding out the rough edges in crossover.

The role of advanced data technologies in reducing hurdles.

Report sets out self-assessment measures for low- and middle-income countries in their adoption of new health technologies.

Click the title above for a link to open the Pharmaceutical Executive October 2020 issue in an interactive PDF format.

Anne E. White, president, Lilly Oncology, talks about how the lessons she learned from leading a startup helped her to speed Lilly’s drug development from target identification through successful launch

Previewing executive trends thought of by leaders in the pharma industry.

Universal strategy push elicits range of constituency views.

Biopharma must find sustainable models for public policy engagement.